Every material Form 8-K XBiotech Inc. has filed with the SEC since October 03, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
XBiotech's board appointed Dr. Sushma Shivaswamy, who had been interim CEO since December 2025 and remains Chief Scientific Officer, and Jan-Paul Simard as co-chief executive officers effective October 23, 2026. Simard is the son of founder John Simard, and his employment agreement includes a one-time grant of 2,000,000 stock options, which shareholders may weigh alongside the leadership change.
Dr. Sushma Shivaswamy, 48, has been with XBiotech for 17 years and will continue as Chief Scientific Officer with an annual salary of $750,000.
Jan-Paul Simard, 24, joined in 2012; his Executive Employment Agreement is dated October 26, 2026, with a base salary of $150,000, prorated through the end of 2026.
Simard's initial grant is 2,000,000 stock options, exercisable over ten years and vesting over three years in six-month intervals.
XBiotech's President and CEO John Simard is retiring effective December 8, 2025, and will remain Chairman of the Board. Chief Scientific Officer Sushma Shivaswamy has been named interim CEO while keeping her scientific role, with her base salary raised to $750,000; a permanent CEO has not yet been appointed.
John Simard retires as President and CEO effective December 8, 2025, and stays on as Chairman of the Board
Sushma Shivaswamy, 47, named interim CEO effective December 8, 2025, while continuing as Chief Scientific Officer
Shivaswamy's annual base salary increased to $750,000; bonus and full remuneration package to be set by the Compensation Committee later
Simard will serve in a consulting role; the company intends to pay the Severance Amount under his employment agreement
XBiotech entered into an Executive Employment Agreement with CEO and President John Simard, effective October 1, 2025, replacing his prior employment agreements. The agreement sets a $1,250,000 base salary, an annual base bonus of $4,530,442, and severance of three years of salary and bonus if he retires, leaves due to disability, or is terminated without cause.
Agreement signed October 2, 2025, effective October 1, 2025, superseding all prior employment agreements with Mr. Simard
Base salary of $1,250,000 maintained; annual base bonus of $4,530,442, based on the average annual bonus paid over the past five years and determined each year by the Compensation Committee
Severance of three full calendar years of base salary and base bonus on retirement, disability, or termination without cause, paid in cash within 14 days after the release takes effect
If Mr. Simard retires, he will consult for the company for at least 18 months and continue receiving base salary during that period
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every XBiotech Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →